In a strategic move enhancing its presence in the neurology sector, Merz Therapeutics has successfully completed the acquisition of INBRIJA (levodopa inhalation powder) and FAMPYRA (fampridine), along with related assets, from Acorda Therapeutics, Inc. This transaction, valued at USD 185 million in cash, was conducted through a court-structured 363 sale under the U.S. Bankruptcy Code, […]
Britannia Pharmaceuticals, a subsidiary of the British pharma group, has announced successful Phase 3 results for its APO-go/MOVAPO (apomorphine) subcutaneous infusion, marking a significant advancement in the treatment of Parkinson’s disease. The TOLEDO trial demonstrated that apomorphine infusion effectively relieves persistent motor fluctuations in patients whose symptoms are not adequately controlled by oral medications. The […]
